T1	KeyEntity 354 396	small-effect quantitative trait loci (QTL)
T2	KeyEntity 400 432	collagen induced arthritis (CIA)
T3	Entity 457 481	transcriptome approaches
T4	Entity 503 526	genome linkage analysis
T5	Entity 530 540	F2 progeny
T6	Entity 548 585	CIA susceptible and resistant strains
T7	KeyEntity 600 616	small-effect QTL
T8	KeyEntity 686 689	CIA
T9	Entity 771 785	genomic region
T10	KeyEntity 796 799	CIA
T11	Entity 810 841	disease-specific differentially
T12	KeyEntity 859 862	CIA
T13	Entity 877 907	strain-specific differentially
T14	KeyEntity 960 976	small-effect QTL
T15	KeyEntity 989 1001	CIA severity
T16	Entity 1060 1110	train-specific and disease-specific differentially
T17	Entity 1128 1131	CIA
T18	KeyEntity 1207 1223	small-effect QTL
R1	participates_in Arg1:T1 Arg2:T2	
R2	is_subclass_of Arg1:T5 Arg2:T6	
R3	is_part_of Arg1:T9 Arg2:T10	
R4	other_relation Arg1:T11 Arg2:T12	
#1	AnnotatorNotes R4	expressed
R5	regulates Arg1:T14 Arg2:T15	
R6	participates_in Arg1:T16 Arg2:T17	
T19	Entity 439 452	global genome
T20	Entity 10 23	global genome
T21	Entity 28 41	transcriptome
T22	Entity 79 84;88 124	genes small-effect quantitative trait loci
T23	Entity 128 154	collagen-induced arthritis
T24	Entity 1411 1436	rheumatoid arthritis (RA)
T25	Entity 1455 1488	multifactorial autoimmune disease
R7	is_subclass_of Arg1:T24 Arg2:T25	
T26	Entity 1559 1561	RA
T27	Entity 1946 1953	HLA-DR4
T28	Entity 1955 1960	PADI4
T29	Entity 1962 1968	PTPN22
T30	Entity 1973 1978	FCRL3
T31	Entity 1914 1916	RA
T32	Entity 1997 2004	HLA-DR4
T33	Entity 2127 2138;2142 2144	mouse model RA
T34	Entity 2280 2309	quantitative trait loci (QTL)
T35	Entity 2313 2345	collagen-induced arthritis (CIA)
T36	Entity 2386 2388	RA
T37	Entity 2399 2402	QTL
T38	Entity 2404 2408	Cia2
T39	Entity 2446 2458	CIA severity
T40	Entity 2469 2472	QTL
T41	KeyEntity 5935 5940;5951 5955	DBA/1 mice
T42	KeyEntity 5945 5955	FVB/N mice
R8	is_part_of Arg1:T22 Arg2:T23	
T43	Entity 2529 2547	CIA susceptibility
T44	Entity 3085 3088	QTL
T45	Entity 3117 3129	mouse genome
R9	is_part_of Arg1:T44 Arg2:T45	
T46	Entity 3765 3804	Microarray-based global gene expression
T47	Entity 4046 4065	expression patterns
T48	Entity 4073 4102	disease-related cells/tissues
T49	Entity 4113 4127	ideal controls
T50	Entity 4199 4223	RA and its animal models
T51	Entity 4259 4268	arthritis
T52	Entity 29796 29809;29821 29842	Visualisation chromosomal locations
T53	Entity 28577 28589	DBA/1 strain
T54	Entity 28597 28629	collagen-induced arthritis (CIA)
T55	Entity 28662 28684	post-immunisation (PI)
T56	Entity 28686 28709	onset of arthritis (OA)
T57	Entity 28714 28736	chronic arthritis (CA)
T58	Entity 28757 28775	naïve control (NC)
T59	Entity 27933 27965	collagen-induced arthritis (CIA)
T60	Entity 28047 28052;28063 28070	DBA/1 strains
T61	Entity 28057 28070	FVB/N strains
T62	Entity 28103 28106	CIA
T63	Entity 28218 28221	CIA
T64	Entity 28250 28274	naive control (NC) phase
T65	Entity 28289 28317	post-immunisation (PI) phase
T66	Entity 28336 28365	onset of arthritis (OA) phase
T67	Entity 28386 28414	chronic arthritis (CA) phase
T68	Entity 5050 5073	small-effect QTL of CIA
T69	Entity 5144 5147	CIA
T70	Entity 5260 5270;5278 5293;5324 5331	F2 progeny CIA susceptible strains
T71	KeyEntity 5295 5300	DBA/1
T72	KeyEntity 5317 5322	FVB/N
T73	Entity 5260 5270;5278 5281;5306 5315;5324 5331	F2 progeny CIA resistant strains
T74	Entity 5353 5381	genome-wide linkage analysis
T75	Entity 5399 5424	identify small-effect QTL
T76	Entity 5507 5512;5523 5530	DBA/1 strains
T77	Entity 5517 5530	FVB/N strains
T78	Entity 5470 5494	gene expression patterns
R10	is_part_of Arg1:T78 Arg2:T76	
R11	is_part_of Arg1:T78 Arg2:T77	
T79	Entity 5663 5691	genomic region linked to CIA
T80	Entity 5702 5733	disease-specific differentially
T81	Entity 5751 5754	CIA
R12	other_relation Arg1:T80 Arg2:T81	
#2	AnnotatorNotes R12	expressed
T82	Entity 5769 5799	strain-specific differentially
T83	Entity 5850 5853	CIA
R13	other_relation Arg1:T82 Arg2:T83	
#3	AnnotatorNotes R13	expressed
T84	KeyEntity 6223 6226	CIA
T85	KeyEntity 6347 6353	DBA/1J
T86	KeyEntity 6355 6360	FVB/N
T87	Entity 6365 6391	(DBA/1J × FVB/N)F2 progeny
T88	Entity 6828 6833;6845 6849	FVB/N mice
T89	Entity 6838 6849	DBA/1J mice
T90	Entity 6973 6979;6983 6986	phases CIA
T91	Entity 6988 7013	namely naive control (NC)
T92	Entity 7015 7037	post-immunisation (PI)
T93	Entity 7039 7062	onset of arthritis (OA)
T94	Entity 7067 7089	chronic arthritis (CA)
R14	is_subclass_of Arg1:T91 Arg2:T90	
R15	is_subclass_of Arg1:T92 Arg2:T90	
R16	is_subclass_of Arg1:T93 Arg2:T90	
R17	is_subclass_of Arg1:T94 Arg2:T90	
T95	Entity 7105 7113	NC group
T96	Entity 7124 7142	non-immunised mice
R18	is_part_of Arg1:T96 Arg2:T95	
T97	Entity 7883 7905	microsatellite markers
T98	Entity 8299 8316	Lymph nodes (LNs)
T99	Entity 8362 8383	total RNA preparation
T100	Entity 8995 9008;9016 9032	Normalisation expression level
T101	Entity 9560 9580	false discovery rate
T102	Entity 9666 9700	proportion of false-positive genes
T103	Entity 9703 9731	Hierarchical gene clustering
T104	KeyEntity 9809 9812	CIA
T105	Entity 9939 9970	Pearson correlation coefficient
T106	Entity 10475 10509	QTL controlling CIA susceptibility
T107	KeyEntity 10513 10539	(DBA/1 × FVB/N) F2 progeny
R19	is_part_of Arg1:T106 Arg2:T107	
T108	Entity 10549 10558;10562 10580	phenotype arthritis severity
T109	KeyEntity 10596 10600	Cia2
T110	KeyEntity 10699 10703	Cia2
T111	Entity 10794 10810	small-effect QTL
T112	Entity 10817 10837	contributions to CIA
T113	Entity 10929 10955	potential small-effect QTL
T114	Entity 10988 11020	lower threshold value of linkage
T115	KeyEntity 11060 11087	main candidate gene of Cia2
T116	Entity 11089 11117	complement component C5 (Hc)
T117	Entity 11150 11165	CIA development
R20	regulates Arg1:T115 Arg2:T117	
T118	KeyEntity 11182 11194	FVB/N strain
T119	Entity 11198 11210	C5 deficient
R21	other_relation Arg1:T119 Arg2:T118	
#4	AnnotatorNotes R21	attribute
T120	Entity 11282 11302	masking effect of C5
T121	Entity 11225 11241;11251 11265	small-effect QTL masked by Cia2
T122	Entity 11317 11333	linkage analysis
T123	Entity 11500 11525	phenotype of CIA severity
T124	Entity 11609 11625	small-effect QTL
T125	Entity 11642 11681	chromosomes 5, 6, 7, 10, 11, 16, and 17
R22	is_part_of Arg1:T124 Arg2:T125	
T126	Entity 11763 11768;11776 11797	DBA/1 susceptibility allele
T127	Entity 11813 11818;11826 11847	FVB/N susceptibility allele
T128	KeyEntity 26539 26544;26555 26562	DBA/1 strains
T129	KeyEntity 26549 26562	FVB/N strains
T130	Entity 26627 26630	CIA
T131	Entity 26632 26634	NA
T132	Entity 26636 26638	PI
T133	Entity 26640 26642	OA
T134	Entity 26647 26649	CA
T135	Entity 24850 24872;24877 24893	search candidate genes small-effect QTL
T136	Entity 24954 24970	small-effect QTL
T137	Entity 24982 25000	CIA susceptibility
R23	regulates Arg1:T136 Arg2:T137	
T138	Entity 24932 24947	candidate genes
R24	other_relation Arg1:T136 Arg2:T138	
#5	AnnotatorNotes R24	attribute
T139	Entity 25087 25103	congenic animals
T140	Entity 25118 25134	small-effect QTL
T141	Entity 25156 25169	high P values
T142	Entity 25187 25222	previously-identified arthritis QTL
T143	Entity 25247 25276	investigating candidate genes
T144	Entity 25288 25293;25304 25311	mouse studies
T145	Entity 25298 25311	human studies
T146	Entity 25445 25459	knock-out mice
T147	Entity 25479 25503	role of the genes in CIA
T148	Entity 25544 25556;25571 25573	human genome RA
T149	Entity 25657 25667	RA cohorts
T150	Entity 25621 25645	case-control association
T151	Entity 25599 25614	candidate genes
T153	Entity 12440 12467	(DBA/1 × BALB/C) F2 progeny
T152	Entity 12363 12376	Locus 1 and 2
T154	Entity 12390 12405	Cia13 and Cia14
T155	Entity 12421 12436	severity of CIA
R25	regulates Arg1:T154 Arg2:T155	
T156	Entity 12474 12481	Locus 5
T157	Entity 12493 12506	chromosome 10
R26	is_part_of Arg1:T156 Arg2:T157	
T158	Entity 12551 12577	(DBA/1 × B10.Q) F2 progeny
T159	Entity 12584 12591	Locus 6
T160	Entity 12521 12525	Cia8
T161	Entity 12606 12611	Pgia7
T162	Entity 12628 12683	susceptibility to proteoglycan-induced arthritis (PGIA)
R27	regulates Arg1:T159 Arg2:T162	
T163	Entity 12706 12733	(BALB/C × DBA/2) F2 progeny
T164	Entity 12777 12793	small-effect QTL
T165	Entity 12839 12851	linked to RA
T166	Entity 12902 12922	chromosome 22 and 12
T167	Entity 12968 12981	chromosome 12
T168	Entity 13039 13052	chromosome 21
T169	Entity 13039 13049;13057 13059	chromosome 10
T170	Entity 13103 13116	chromosome 17
T171	Entity 13163 13175	chromosome 3
T172	Entity 13764 13810	strain-specific differentially expressed genes
T173	KeyEntity 13868 13873;13884 13891	DBA/1 strains
T174	KeyEntity 13878 13891	FVB/N strains
T175	Entity 13904 13917	phases of CIA
T176	Entity 13929 13931	NC
T177	Entity 13933 13935	PI
T178	Entity 13937 13939	OA
T179	Entity 13944 13946	CA
R28	is_subclass_of Arg1:T176 Arg2:T175	
R29	is_subclass_of Arg1:T177 Arg2:T175	
R30	is_subclass_of Arg1:T178 Arg2:T175	
R31	is_subclass_of Arg1:T179 Arg2:T175	
T180	Entity 14732 14745	CIA induction
T181	Entity 14747 14760	PI, OA and CA
T182	Entity 14839 14893	disease-specific differentially expressed genes in CIA
T183	Entity 14942 14958	expressed in LNs
T184	Entity 14966 14969	CIA
R32	is_part_of Arg1:T183 Arg2:T184	
T185	Entity 15028 15030	PI
T186	Entity 15032 15034	OA
T187	Entity 15039 15041	CA
T188	Entity 15066 15074	NC group
T189	Entity 15555 15565	PI with OA
T191	Entity 15567 15577	PI with CA
T190	Entity 15582 15592	OA with CA
T192	Entity 15725 15742	CIA in DBA/1 mice
T193	Entity 15793 15816	gene expression pattern
T194	Entity 15824 15827	CIA
R33	is_part_of Arg1:T193 Arg2:T194	
T195	Entity 15842 15871	hierarchical cluster analysis
T196	Entity 15893 15910	Six gene clusters
T197	Entity 16015 16024	Cluster I
T198	Entity 16057 16062	genes
T199	Entity 16073 16107	upregulated after induction of CIA
R34	other_relation Arg1:T199 Arg2:T198	
#6	AnnotatorNotes R34	attribute
T200	Entity 16149 16153;16161 16172	peak onset phase
T201	Entity 16277 16287	Cluster II
T202	Entity 16363 16367;16375 16395	peak chronic phase of CIA
T203	Entity 16435 16450	immune response
T204	Entity 16452 16470	organelle membrane
T205	Entity 16475 16505	extracellular region and space
T206	Entity 16507 16518	Cluster III
T207	Entity 16552 16566;16571 16579	upregulated at PI phase
T208	Entity 16612 16634	intercellular junction
T209	Entity 16687 16697	cluster IV
T210	Entity 16731 16747;16752 16765	downregultaed at chronic phase
T211	Entity 16807 16831	lymphocyte proliferation
T212	Entity 16833 16850	T cell activation
T213	Entity 16852 16867	protein binding
T214	Entity 16883 16903	notch signal pathway
T215	Entity 16905 16914	Cluster V
T216	Entity 16936 16952;16957 16965	downregulated at PI phase
T217	Entity 16967 16977	Cluster VI
T218	Entity 16996 17012;17017 17025	downregulated at OA phase
T219	Entity 17244 17264	CIA small-effect QTL
T220	Entity 17607 17646	chromosomes, 5, 6, 7, 10, 11, 16 and 17
T221	KeyEntity 18130 18136	hspa1a
T222	KeyEntity 18141 18146	Oas1a
T223	Entity 18153 18167;18172 18187	upregulated at OA phase of CIA
T225	KeyEntity 18192 18197	Oas1a
T226	Entity 18207 18221;18226 18234	upregulated at PI phase
T227	Entity 18288 18304;18309 18329	downregulated at chronic phase of CIA
T224	KeyEntity 18501 18507	H2-Q10
T228	KeyEntity 18509 18515	Mapk14
T229	KeyEntity 18517 18522	Pscd1
T230	KeyEntity 18524 18529	Kpnb1
T231	KeyEntity 18534 18538	Wdr1
T232	KeyEntity 18564 18570	H2-Q10
T233	Entity 18590 18607	higher expression
T234	Entity 18615 18620	DBA/1
T235	Entity 18874 18918;18937 18945	functional cluster of protein kinase cascade enriched
T236	KeyEntity 19029 19035	Mapk14
T237	KeyEntity 19037 19045	Mapk8ip3
T238	KeyEntity 19047 19053	Stat5a
T239	KeyEntity 19058 19063	Gna12
T240	Entity 19128 19153	identify small-effect QTL
T241	Entity 19160 19170	F2 progeny
R35	is_part_of Arg1:T240 Arg2:T241	
T242	Entity 19172 19188	Small-effect QTL
T243	Entity 19412 19428	small-effect QTL
T244	Entity 19444 19472	susceptibility genes for CIA
T245	Entity 19498 19514	linkage analysis
T246	Entity 19566 19582	C5+/+ F2 progeny
T247	Entity 19591 19607	C5+/- F2 progeny
T248	Entity 19552 19561	F progeny
T249	Entity 19779 19805	overlap with arthritis QTL
T250	Entity 19839 19857	loci 1, 2, 5 and 6
T251	Entity 19872 19889	syntenic analysis
T252	Entity 19987 19999	linked to RA
T253	Entity 19979 19982	QTL
T254	Entity 20045 20058	DBA/1 alleles
T255	Entity 20067 20094	arthritis-enhancing alleles
R36	other_relation Arg1:T255 Arg2:T254	
#7	AnnotatorNotes R36	attribute
T257	Entity 20200 20220	susceptibility genes
T258	Entity 20241 20257	resistant strain
T256	Entity 20274 20286	loci 2 and 7
T259	Entity 20297 20335	overlap with two arthritis-related QTL
T260	Entity 20382 20389	Locus 2
T261	Entity 20432 20437	Cia27
T262	Entity 20441 20493	QTL controlling IgG2a antibody levels to collagen II
R37	other_relation Arg1:T262 Arg2:T261	
#8	AnnotatorNotes R37	attribute
T263	Entity 20526 20529	QTL
T264	Entity 20611 20623	CIA severity
T265	Entity 20577 20581	gene
R38	regulates Arg1:T265 Arg2:T264	
T266	Entity 20627 20679	controlling the IgG2a antibody levels to collagen II
R39	other_relation Arg1:T266 Arg2:T265	
#9	AnnotatorNotes R39	attribute
R40	is_part_of Arg1:T265 Arg2:T263	
T267	Entity 20686 20693	Locus 7
T268	Entity 20697 20710	chromosome 16
R41	is_part_of Arg1:T267 Arg2:T268	
T269	Entity 20725 20728	Lp1
T270	Entity 20745 20769	lymphocyte proliferation
R42	regulates Arg1:T267 Arg2:T270	
T271	Entity 20819 20825	loci 8
T272	Entity 20829 20842	chromosome 17
R43	is_part_of Arg1:T271 Arg2:T272	
T273	Entity 20852 20898	lymphocyte adherence during development of CIA
R44	regulates Arg1:T273 Arg2:T271	
T274	Entity 20961 20973	CIA severity
T275	Entity 20915 20919	gene
R45	regulates Arg1:T275 Arg2:T274	
T276	Entity 20931 20947	small-effect QTL
R46	is_part_of Arg1:T275 Arg2:T276	
T277	Entity 20982 21022	controlling arthritis-related phenotypes
T278	Entity 23927 23952	identify small-effect QTL
T279	Entity 23968 23993	potential candidate genes
T280	Entity 24125 24147	false positive results
T281	Entity 24042 24067	low statistical threshold
T282	Entity 24072 24105	small number of animals per group
T283	Entity 24299 24306	locus 4
T284	Entity 24329 24340	low P value
R47	other_relation Arg1:T284 Arg2:T283	
#10	AnnotatorNotes R47	attribute
T285	Entity 24350 24361;24371 24406	not overlap previously identified arthritis QTL
T286	Entity 22823 22839	small-effect QTL
T287	Entity 22859 22883	gene expression patterns
T288	Entity 22891 22894	CIA
R48	is_part_of Arg1:T287 Arg2:T288	
T289	KeyEntity 23190 23196	Mapk14
T290	Entity 23200 23226	candidate gene for locus 8
T291	Entity 23243 23292	p38 mitogen-activated protein kinase (MAPK) alpha
R49	other_relation Arg1:T291 Arg2:T289	
#11	AnnotatorNotes R49	attribute
R50	other_relation Arg1:T290 Arg2:T289	
#12	AnnotatorNotes R50	attribute
T292	Entity 23308 23351	production of arthritis-essential cytokines
R51	regulates Arg1:T289 Arg2:T292	
T293	Entity 23361 23383	tumour necrosis factor
T294	Entity 23388 23401	interleukin-1
R52	is_subclass_of Arg1:T293 Arg2:T292	
R53	is_subclass_of Arg1:T294 Arg2:T292	
T295	Entity 23418 23440	inhibitors of p38 MAPK
T296	Entity 23447 23468	attenuate CIA in rats
T297	Entity 23479 23487	p38 MAPK
T298	Entity 23512 23536	therapeutic target in RA
T299	KeyEntity 23543 23549	Stat5a
T300	Entity 23553 23578	candidate gene for loci 6
R54	other_relation Arg1:T300 Arg2:T299	
#13	AnnotatorNotes R54	attribute
T301	Entity 23609 23629	lymphoid development
T302	Entity 23609 23617;23634 23649	lymphoid differentiation
R55	regulates Arg1:T299 Arg2:T301	
R56	regulates Arg1:T299 Arg2:T302	
T303	Entity 23656 23677	Stat5a-deficient mice
T304	Entity 23695 23709	lose tolerance
T305	Entity 23728 23762	development of autoimmune diseases
R57	other_relation Arg1:T305 Arg2:T303	
#14	AnnotatorNotes R57	attribute
T306	KeyEntity 23764 23770	Stat5a
T307	Entity 23819 23876	maintenance of the CD4+CD25+ regulatory T cell population
T308	Entity 23801 23810	tolerance
R58	participates_in Arg1:T306 Arg2:T308	
R59	other_relation Arg1:T307 Arg2:T306	
#15	AnnotatorNotes R59	attribute
T309	Entity 21066 21099	detect gene expression during CIA
T310	Entity 21194 21225	detected gene expression in LNs
T311	Entity 21233 21236	CIA
R60	is_part_of Arg1:T310 Arg2:T311	
T312	Entity 21271 21302	gene expression patterns in LNs
T313	Entity 21311 21334	genetically susceptible
T314	Entity 21311 21322;21339 21356	genetically resistant strains
T315	Entity 21375 21388	phases of CIA
T316	Entity 21422 21437	regulated genes
T317	Entity 21450 21486	concentrated at the PI and CA phases
T318	Entity 21595 21622	biological responses in LNs
T319	Entity 21644 21660	PI and CA phases
T320	Entity 21628 21636	stronger
R61	other_relation Arg1:T320 Arg2:T318	
#16	AnnotatorNotes R61	attribute
T321	Entity 21851 21861	cluster IV
T322	Entity 21892 21918	higher expression in DBA/1
T323	Entity 21984 22027	opposite expression pattern in the CA phase
T324	Entity 22029 22051	GO term classification
T325	Entity 22072 22077	genes
T326	Entity 22094 22118	lymphocyte proliferation
R62	participates_in Arg1:T325 Arg2:T326	
T327	Entity 22094 22104;22123 22133	lymphocyte activation
R63	participates_in Arg1:T325 Arg2:T327	
T328	Entity 22151 22182;22187 22201	lymphocytes in the DBA/1 strain more activated
T329	Entity 22436 22467	upregulated in the DBA/1 strain
T330	Entity 22394 22399	genes
R64	other_relation Arg1:T329 Arg2:T330	
#17	AnnotatorNotes R64	attribute
T331	Entity 22472 22475;22483 22506	not FVB/N strain during CIA
T332	Entity 22546 22585	higher antibody response to collagen II
T333	Entity 22602 22614	DBA/1 strain
R65	is_part_of Arg1:T332 Arg2:T333	
